Dr Reddy's Laboratories Ltd banner

Dr Reddy's Laboratories Ltd
NSE:DRREDDY

Watchlist Manager
Dr Reddy's Laboratories Ltd Logo
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Watchlist
Price: 1 318 INR -0.98% Market Closed
Market Cap: ₹1.1T

Dr Reddy's Laboratories Ltd
Short-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Dr Reddy's Laboratories Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Short-Term Debt
₹0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Short-Term Debt
₹0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Short-Term Debt
₹0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Short-Term Debt
₹28.1B
CAGR 3-Years
N/A
CAGR 5-Years
-7%
CAGR 10-Years
12%
Lupin Ltd
NSE:LUPIN
Short-Term Debt
₹42.4B
CAGR 3-Years
2%
CAGR 5-Years
12%
CAGR 10-Years
9%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Short-Term Debt
₹0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Dr Reddy's Laboratories Ltd
Glance View

In the bustling world of pharmaceuticals, Dr. Reddy's Laboratories Ltd. stands as a testament to innovation and resilience. Founded in 1984 by Dr. K. Anji Reddy, the company embarked on a journey to provide affordable and accessible medicine. Dr. Reddy's merged scientific rigor with a clear vision to eliminate health disparities worldwide. From creating complex generics and active pharmaceutical ingredients (APIs) to providing differentiated formulations, the company has built a strong foundation in both developed markets, like the United States and Europe, as well as in emerging markets such as India, Russia, and the CIS countries. This global footprint ensures that while many pharmaceutical companies are battling regulatory challenges and pricing pressures, Dr. Reddy's stays agile and competitive. The company's revenue streams primarily derive from its diverse portfolio of generic drugs, APIs, branded formulations, biologics, and proprietary products. Each sector is a strategic puzzle piece that enhances its market presence and ensures supply chain efficiency. Dr. Reddy's invests heavily in research and development to bolster its pipeline of future medications, aiming to address unmet medical needs and introduce value-added products. By leveraging strategic alliances and forging partnerships in development and distribution, the company adeptly navigates the complex landscape of the pharmaceutical industry, ensuring sustainable growth and reaffirming its commitment to affordable healthcare globally.

DRREDDY Intrinsic Value
871.39 INR
Overvaluation 34%
Intrinsic Value
Price ₹1 318

See Also

What is Dr Reddy's Laboratories Ltd's Short-Term Debt?
Short-Term Debt
0 INR

Based on the financial report for Dec 31, 2025, Dr Reddy's Laboratories Ltd's Short-Term Debt amounts to 0 INR.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett